Aurobindo Pharma delivered an operational sweep in the second quarter. Consolidated net profit surged 32.8% year-on-year to ₹1,126 crore for the quarter ended September 30, up from ₹848 crore in the corresponding period last fiscal. AirNews blew past consensus street estimates, underpinned by record operating revenue and broad-based export momentum.
Shares of the pharmaceutical major closed 0.62% higher at ₹1,705 on November 4 ahead of the earnings release.
Revenue from operations leaped 23.9% to ₹10,263 crore compared to ₹8,286 crore a year ago, comfortably beating analyst expectations of ₹9,719 crore. Operating leverage kicked in with force. Earnings before interest, tax, depreciation, and amortisation (EBITDA) climbed 28.4% to ₹2,155 crore against ₹1,678 crore last year, outpacing market forecasts of ₹2,006 crore. Operating margin expanded 70 basis points to 21%, crossing the projected 20.6% threshold. Diluted earnings per share arrived at ₹19.57.
Growth was broad and disciplined across international markets. The United States—the company’s primary revenue engine—jumped 25% year-on-year to ₹4,555 crore ($477 million). European formulations clocked ₹3,161 crore (€288 million), advancing 27%, while growth markets advanced 16% to ₹1,026 crore ($107 million). Antiretroviral product revenue stood at ₹359 crore ($38 million). Regulatory pipelines cleared steadily, with the United States Food and Drug Administration granting final approval for 12 products during the three-month stretch. Research and development outlay rose to ₹376 crore from ₹344 crore in the preceding quarter.
| Financial Metric | Q2 FY27 | Q2 FY26 | YoY Change | Consensus Estimate |
|---|---|---|---|---|
| Revenue from Operations | ₹10,263 cr | ₹8,286 cr | +23.9% | ₹9,719 cr |
| EBITDA | ₹2,155 cr | ₹1,678 cr | +28.4% | ₹2,006 cr |
| EBITDA Margin | 21.0% | 20.3% | +70 bps | 20.6% |
| Net Profit | ₹1,126 cr | ₹848 cr | +32.8% | — |
Cash flow generation remained solid despite aggressive capital deployment. The company converted operational gains into $146 million of free cash flow after funding strategic capital expenditures, lifting its total net cash position—including treasury investments—to $189 million at the close of September.
Business fundamentals delivered the upside, according to regulatory disclosures. K. Nithyananda Reddy, Vice-Chairman and Managing Director of Aurobindo Pharma, stated that quarterly execution tracked organic momentum across primary business units alongside the integration of strategic inorganic acquisitions that fortified manufacturing capabilities. Reddy noted that management will maintain operational discipline while driving long-term portfolio diversification.
Shareholders will receive an immediate cash payout. The company's board approved an interim dividend of ₹7 per equity share of face value ₹1 each—representing a 700% payout. The board fixed November 11, 2026, as the record date to determine eligible investors, with distribution scheduled on or before November 20, 2026.
| Basic & Diluted EPS | ₹19.57 | — | — | — |